Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes : a multicentre 6-month randomised controlled trial
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Closed-loop insulin delivery systems have the potential to address suboptimal glucose control in children and adolescents with type 1 diabetes. We compared safety and efficacy of the Cambridge hybrid closed-loop algorithm with usual care over 6 months in this population.
METHODS: In a multicentre, multinational, parallel randomised controlled trial, participants aged 6-18 years using insulin pump therapy were recruited at seven UK and five US paediatric diabetes centres. Key inclusion criteria were diagnosis of type 1 diabetes for at least 12 months, insulin pump therapy for at least 3 months, and screening HbA1c levels between 53 and 86 mmol/mol (7·0-10·0%). Using block randomisation and central randomisation software, we randomly assigned participants to either closed-loop insulin delivery (closed-loop group) or to usual care with insulin pump therapy (control group) for 6 months. Randomisation was stratified at each centre by local baseline HbA1c. The Cambridge closed-loop algorithm running on a smartphone was used with either (1) a modified Medtronic 640G pump, Medtronic Guardian 3 sensor, and Medtronic prototype phone enclosure (FlorenceM configuration), or (2) a Sooil Dana RS pump and Dexcom G6 sensor (CamAPS FX configuration). The primary endpoint was change in HbA1c at 6 months combining data from both configurations. The primary analysis was done in all randomised patients (intention to treat). Trial registration ClinicalTrials.gov, NCT02925299.
FINDINGS: Of 147 people initially screened, 133 participants (mean age 13·0 years [SD 2·8]; 57% female, 43% male) were randomly assigned to either the closed-loop group (n=65) or the control group (n=68). Mean baseline HbA1c was 8·2% (SD 0·7) in the closed-loop group and 8·3% (0·7) in the control group. At 6 months, HbA1c was lower in the closed-loop group than in the control group (between-group difference -3·5 mmol/mol (95% CI -6·5 to -0·5 [-0·32 percentage points, -0·59 to -0·04]; p=0·023). Closed-loop usage was low with FlorenceM due to failing phone enclosures (median 40% [IQR 26-53]), but consistently high with CamAPS FX (93% [88-96]), impacting efficacy. A total of 155 adverse events occurred after randomisation (67 in the closed-loop group, 88 in the control group), including seven severe hypoglycaemia events (four in the closed-loop group, three in the control group), two diabetic ketoacidosis events (both in the closed-loop group), and two non-treatment-related serious adverse events. There were 23 reportable hyperglycaemia events (11 in the closed-loop group, 12 in the control group), which did not meet criteria for diabetic ketoacidosis.
INTERPRETATION: The Cambridge hybrid closed-loop algorithm had an acceptable safety profile, and improved glycaemic control in children and adolescents with type 1 diabetes. To ensure optimal efficacy of the closed-loop system, usage needs to be consistently high, as demonstrated with CamAPS FX.
FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
The Lancet. Digital health - 4(2022), 4 vom: 26. Apr., Seite e245-e255 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ware, Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 25.04.2022 Date Revised 27.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT02925299 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2589-7500(22)00020-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338038132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338038132 | ||
| 003 | DE-627 | ||
| 005 | 20240229163252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2589-7500(22)00020-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM338038132 | ||
| 035 | |a (NLM)35272971 | ||
| 035 | |a (PII)S2589-7500(22)00020-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ware, Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes |b a multicentre 6-month randomised controlled trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2022 | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02925299 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Closed-loop insulin delivery systems have the potential to address suboptimal glucose control in children and adolescents with type 1 diabetes. We compared safety and efficacy of the Cambridge hybrid closed-loop algorithm with usual care over 6 months in this population | ||
| 520 | |a METHODS: In a multicentre, multinational, parallel randomised controlled trial, participants aged 6-18 years using insulin pump therapy were recruited at seven UK and five US paediatric diabetes centres. Key inclusion criteria were diagnosis of type 1 diabetes for at least 12 months, insulin pump therapy for at least 3 months, and screening HbA1c levels between 53 and 86 mmol/mol (7·0-10·0%). Using block randomisation and central randomisation software, we randomly assigned participants to either closed-loop insulin delivery (closed-loop group) or to usual care with insulin pump therapy (control group) for 6 months. Randomisation was stratified at each centre by local baseline HbA1c. The Cambridge closed-loop algorithm running on a smartphone was used with either (1) a modified Medtronic 640G pump, Medtronic Guardian 3 sensor, and Medtronic prototype phone enclosure (FlorenceM configuration), or (2) a Sooil Dana RS pump and Dexcom G6 sensor (CamAPS FX configuration). The primary endpoint was change in HbA1c at 6 months combining data from both configurations. The primary analysis was done in all randomised patients (intention to treat). Trial registration ClinicalTrials.gov, NCT02925299 | ||
| 520 | |a FINDINGS: Of 147 people initially screened, 133 participants (mean age 13·0 years [SD 2·8]; 57% female, 43% male) were randomly assigned to either the closed-loop group (n=65) or the control group (n=68). Mean baseline HbA1c was 8·2% (SD 0·7) in the closed-loop group and 8·3% (0·7) in the control group. At 6 months, HbA1c was lower in the closed-loop group than in the control group (between-group difference -3·5 mmol/mol (95% CI -6·5 to -0·5 [-0·32 percentage points, -0·59 to -0·04]; p=0·023). Closed-loop usage was low with FlorenceM due to failing phone enclosures (median 40% [IQR 26-53]), but consistently high with CamAPS FX (93% [88-96]), impacting efficacy. A total of 155 adverse events occurred after randomisation (67 in the closed-loop group, 88 in the control group), including seven severe hypoglycaemia events (four in the closed-loop group, three in the control group), two diabetic ketoacidosis events (both in the closed-loop group), and two non-treatment-related serious adverse events. There were 23 reportable hyperglycaemia events (11 in the closed-loop group, 12 in the control group), which did not meet criteria for diabetic ketoacidosis | ||
| 520 | |a INTERPRETATION: The Cambridge hybrid closed-loop algorithm had an acceptable safety profile, and improved glycaemic control in children and adolescents with type 1 diabetes. To ensure optimal efficacy of the closed-loop system, usage needs to be consistently high, as demonstrated with CamAPS FX | ||
| 520 | |a FUNDING: National Institute of Diabetes and Digestive and Kidney Diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Boughton, Charlotte K |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Janet M |e verfasserin |4 aut | |
| 700 | 1 | |a Wilinska, Malgorzata E |e verfasserin |4 aut | |
| 700 | 1 | |a Tauschmann, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Denvir, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Thankamony, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Fiona M |e verfasserin |4 aut | |
| 700 | 1 | |a Wadwa, R Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Buckingham, Bruce A |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Nikki |e verfasserin |4 aut | |
| 700 | 1 | |a DiMeglio, Linda A |e verfasserin |4 aut | |
| 700 | 1 | |a Mauras, Nelly |e verfasserin |4 aut | |
| 700 | 1 | |a Besser, Rachel E J |e verfasserin |4 aut | |
| 700 | 1 | |a Ghatak, Atrayee |e verfasserin |4 aut | |
| 700 | 1 | |a Weinzimer, Stuart A |e verfasserin |4 aut | |
| 700 | 1 | |a Hood, Korey K |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, D Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Kanapka, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Kollman, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Sibayan, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Roy W |e verfasserin |4 aut | |
| 700 | 1 | |a Hovorka, Roman |e verfasserin |4 aut | |
| 700 | 0 | |a DAN05 Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Hovorka, R |e investigator |4 oth | |
| 700 | 1 | |a Acerini, C L |e investigator |4 oth | |
| 700 | 1 | |a Thankamony, A |e investigator |4 oth | |
| 700 | 1 | |a Allen, J M |e investigator |4 oth | |
| 700 | 1 | |a Boughton, C K |e investigator |4 oth | |
| 700 | 1 | |a Dovc, K |e investigator |4 oth | |
| 700 | 1 | |a Dunger, D B |e investigator |4 oth | |
| 700 | 1 | |a Ware, J |e investigator |4 oth | |
| 700 | 1 | |a Musolino, G |e investigator |4 oth | |
| 700 | 1 | |a Tauschmann, M |e investigator |4 oth | |
| 700 | 1 | |a Wilinska, M E |e investigator |4 oth | |
| 700 | 1 | |a Hayes, J F |e investigator |4 oth | |
| 700 | 1 | |a Hartnell, S |e investigator |4 oth | |
| 700 | 1 | |a Slegtenhorst, S |e investigator |4 oth | |
| 700 | 1 | |a Ruan, Y |e investigator |4 oth | |
| 700 | 1 | |a Haydock, M |e investigator |4 oth | |
| 700 | 1 | |a Mangat, J |e investigator |4 oth | |
| 700 | 1 | |a Denvir, L |e investigator |4 oth | |
| 700 | 1 | |a Kanthagnany, S K |e investigator |4 oth | |
| 700 | 1 | |a Law, J |e investigator |4 oth | |
| 700 | 1 | |a Randell, T |e investigator |4 oth | |
| 700 | 1 | |a Sachdev, P |e investigator |4 oth | |
| 700 | 1 | |a Saxton, M |e investigator |4 oth | |
| 700 | 1 | |a Coupe, A |e investigator |4 oth | |
| 700 | 1 | |a Stafford, S |e investigator |4 oth | |
| 700 | 1 | |a Ball, A |e investigator |4 oth | |
| 700 | 1 | |a Keeton, R |e investigator |4 oth | |
| 700 | 1 | |a Cresswell, R |e investigator |4 oth | |
| 700 | 1 | |a Crate, L |e investigator |4 oth | |
| 700 | 1 | |a Cripps, H |e investigator |4 oth | |
| 700 | 1 | |a Fazackerley, H |e investigator |4 oth | |
| 700 | 1 | |a Looby, L |e investigator |4 oth | |
| 700 | 1 | |a Navarra, H |e investigator |4 oth | |
| 700 | 1 | |a Saddington, C |e investigator |4 oth | |
| 700 | 1 | |a Smith, V |e investigator |4 oth | |
| 700 | 1 | |a Verhoeven, V |e investigator |4 oth | |
| 700 | 1 | |a Bratt, S |e investigator |4 oth | |
| 700 | 1 | |a Khan, N |e investigator |4 oth | |
| 700 | 1 | |a Moyes, L |e investigator |4 oth | |
| 700 | 1 | |a Sandhu, K |e investigator |4 oth | |
| 700 | 1 | |a West, C |e investigator |4 oth | |
| 700 | 1 | |a Wadwa, R P |e investigator |4 oth | |
| 700 | 1 | |a Alonso, G |e investigator |4 oth | |
| 700 | 1 | |a Forlenza, G |e investigator |4 oth | |
| 700 | 1 | |a Slover, R |e investigator |4 oth | |
| 700 | 1 | |a Towers, L |e investigator |4 oth | |
| 700 | 1 | |a Berget, C |e investigator |4 oth | |
| 700 | 1 | |a Coakley, A |e investigator |4 oth | |
| 700 | 1 | |a Escobar, E |e investigator |4 oth | |
| 700 | 1 | |a Jost, E |e investigator |4 oth | |
| 700 | 1 | |a Lange, S |e investigator |4 oth | |
| 700 | 1 | |a Messer, L |e investigator |4 oth | |
| 700 | 1 | |a Thivener, K |e investigator |4 oth | |
| 700 | 1 | |a Campbell, F M |e investigator |4 oth | |
| 700 | 1 | |a Yong, J |e investigator |4 oth | |
| 700 | 1 | |a Metcalfe, E |e investigator |4 oth | |
| 700 | 1 | |a Allen, M |e investigator |4 oth | |
| 700 | 1 | |a Ambler, S |e investigator |4 oth | |
| 700 | 1 | |a Waheed, S |e investigator |4 oth | |
| 700 | 1 | |a Exall, J |e investigator |4 oth | |
| 700 | 1 | |a Tulip, J |e investigator |4 oth | |
| 700 | 1 | |a Buckingham, B A |e investigator |4 oth | |
| 700 | 1 | |a Ekhlaspour, L |e investigator |4 oth | |
| 700 | 1 | |a Maahs, D |e investigator |4 oth | |
| 700 | 1 | |a Norlander, L |e investigator |4 oth | |
| 700 | 1 | |a Jacobson, T |e investigator |4 oth | |
| 700 | 1 | |a Twon, M |e investigator |4 oth | |
| 700 | 1 | |a Weir, C |e investigator |4 oth | |
| 700 | 1 | |a Leverenz, B |e investigator |4 oth | |
| 700 | 1 | |a Keller, J |e investigator |4 oth | |
| 700 | 1 | |a Davis, N |e investigator |4 oth | |
| 700 | 1 | |a Kumaran, A |e investigator |4 oth | |
| 700 | 1 | |a Trevelyan, N |e investigator |4 oth | |
| 700 | 1 | |a Dewar, H |e investigator |4 oth | |
| 700 | 1 | |a Price, G |e investigator |4 oth | |
| 700 | 1 | |a Crouch, G |e investigator |4 oth | |
| 700 | 1 | |a Ensom, R |e investigator |4 oth | |
| 700 | 1 | |a Haskell, L |e investigator |4 oth | |
| 700 | 1 | |a Lueddeke, L M |e investigator |4 oth | |
| 700 | 1 | |a Mauras, N |e investigator |4 oth | |
| 700 | 1 | |a Benson, M |e investigator |4 oth | |
| 700 | 1 | |a Bird, K |e investigator |4 oth | |
| 700 | 1 | |a Englert, K |e investigator |4 oth | |
| 700 | 1 | |a Permuy, J |e investigator |4 oth | |
| 700 | 1 | |a Ponthieux, K |e investigator |4 oth | |
| 700 | 1 | |a Marrero-Hernandez, J |e investigator |4 oth | |
| 700 | 1 | |a DiMeglio, L A |e investigator |4 oth | |
| 700 | 1 | |a Ismail, H |e investigator |4 oth | |
| 700 | 1 | |a Jolivette, H |e investigator |4 oth | |
| 700 | 1 | |a Sanchez, J |e investigator |4 oth | |
| 700 | 1 | |a Woerner, S |e investigator |4 oth | |
| 700 | 1 | |a Kirchner, M |e investigator |4 oth | |
| 700 | 1 | |a Mullen, M |e investigator |4 oth | |
| 700 | 1 | |a Tebbe, M |e investigator |4 oth | |
| 700 | 1 | |a Besser, R Ej |e investigator |4 oth | |
| 700 | 1 | |a Basu, S |e investigator |4 oth | |
| 700 | 1 | |a London, R |e investigator |4 oth | |
| 700 | 1 | |a Makaya, T |e investigator |4 oth | |
| 700 | 1 | |a Ryan, F |e investigator |4 oth | |
| 700 | 1 | |a Megson, C |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Digital health |d 2019 |g 4(2022), 4 vom: 26. Apr., Seite e245-e255 |w (DE-627)NLM300580312 |x 2589-7500 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:4 |g day:26 |g month:04 |g pages:e245-e255 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2589-7500(22)00020-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 4 |b 26 |c 04 |h e245-e255 | ||